Compare · ANEB vs NVO
ANEB vs NVO
Side-by-side comparison of Anebulo Pharmaceuticals Inc. (ANEB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANEB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.28B, about 1218.6x ANEB ($161.1M).
- Over the past year, ANEB is down 68.7% and NVO is down 45.8% - NVO leads by 22.9 points.
- NVO has hit the wire 8 times in the past 4 weeks while ANEB has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for ANEB).
- Company
- Anebulo Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $0.37-15.33%
- $43.97+2.76%
- Market cap
- $161.1M
- $196.28B
- 1M return
- +0.00%
- -6.43%
- 1Y return
- -68.69%
- -45.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANEB
- SEC Form 15-12G filed by Anebulo Pharmaceuticals Inc.
- SEC Form 25 filed by Anebulo Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Anebulo Pharmaceuticals Inc.
- SEC Form 10-Q filed by Anebulo Pharmaceuticals Inc.
- Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
- Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits
- Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
- Amendment: SEC Form SC TO-I/A filed by Anebulo Pharmaceuticals Inc.
- Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care